Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ascentage Pharma Group International (ASPHF)
Suzhou, CN
Ascentage Pharma Group International (ASPHF) is a clinical-stage biotechnology firm that develops novel therapeutic agents. Its primary focus areas include oncological conditions, chronic hepatitis B (HBV), and age-related diseases, with operations concentrated in the United States and Mainland China. A cornerstone of its pipeline is HQP1351, a BCR-ABL inhibitor specifically engineered to combat BCR-ABL mutants, including those bearing the challenging T315I mutation. This compound is particularly aimed at individuals suffering from chronic phase chronic myeloid leukemia (CML) that has proven resistant to conventional tyrosine kinase inhibitor (TKI) treatments. Ascentage's diverse pipeline further includes APG-2575, an orally administered selective Bcl-2 inhibitor currently in Phase Ib/II clinical studies for hematologic malignancies and solid tumors. Another asset is APG-115, an oral small molecule designed to disrupt the MDM2-p53 protein-protein interaction, also intended for solid tumors and blood cancers. Additionally, APG-1387, a small molecule inhibitor of apoptosis proteins, is being developed for advanced solid tumors and chronic HBV infection. Beyond these, Ascentage is actively advancing APG-1252, a small molecule drug engineered to induce apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins, targeting small cell lung cancer (SCLC), lymphoma, and various other solid tumors. Other ongoing projects include APG-2449 for non-small-cell lung carcinoma, and APG-5918, a promising orally available and selective EED inhibitor with best-in-class potential, currently in the preclinical stage. Furthermore, APG-265 is in IND-enabling studies for hematological and solid malignancies, while UBX1967/1325, aimed at the Bcl family for diabetic macular edema (DME), is undergoing Phase II development. The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical enterprises, as well as respected academic institutions. Notable partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Founded in 2009, Ascentage Pharma's corporate headquarters are situated in Suzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -40.57% | -40.57% | -40.57% | -40.57% | -13.40% | +22.63% | -17.38% | -17.38% | -17.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-43.0% Q4'25: +322.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-150.4% Q4'25: +2.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-237.3% Q4'25: -235.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-211.1% Q4'25: -191.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-139.9% Q4'25: -304.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+20.3% Q4'25: +27.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.81× Q4'25: -0.83× (vs Q4'23)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 1 EPS Ana. |
Dec 2027 10 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.51M
est: 6.93M (+109.6%)
|
12.45M
est: 6.98M (+78.2%)
|
27.91M
est: 38.07M (-26.7%)
|
209.71M
est: 264.25M (-20.6%)
|
221.98M
est: 369.18M (-39.9%)
|
980.65M
est: 1.12B (-12.2%)
|
559.30M
est: 525.09M (+6.5%)
|
949.26M
666.83M – 1.32B
+80.8% YoY
|
1.52B
854.23M – 3.12B
+60.4% YoY
|
2.57B
1.58B – 4.64B
+68.8% YoY
|
3.09B
1.89B – 5.58B
+20.2% YoY
|
5.46B
3.35B – 9.87B
+76.9% YoY
|
| EBITDA |
-1.45B
est: -6.93M (-20,861.5%)
|
-641.77M
est: -6.98M (-9,088.3%)
|
-915.99M
est: -38.07M (-2,306.0%)
|
-835.99M
est: -264.25M (-216.4%)
|
-743.61M
est: -369.18M (-101.4%)
|
-237.63M
est: -947.18M (+74.9%)
|
-1.10B
est: -445.52M (-146.2%)
|
-805.41M
-1.12B – -565.78M
-80.8% YoY
|
-1.29B
-2.64B – -724.78M
-60.4% YoY
|
-2.18B
-3.94B – -1.34B
-68.8% YoY
|
-2.62B
-4.73B – -1.61B
-20.2% YoY
|
-4.64B
-8.37B – -2.84B
-76.9% YoY
|
| EBIT |
-1.48B
est: -6.93M (-21,243.2%)
|
-669.19M
est: -6.98M (-9,480.9%)
|
-815.52M
est: -38.07M (-2,042.1%)
|
-834.39M
est: -264.25M (-215.8%)
|
-836.81M
est: -369.18M (-126.7%)
|
-330.80M
est: -968.40M (+65.8%)
|
-1.18B
est: -455.49M (-159.3%)
|
-823.45M
-1.15B – -578.45M
-80.8% YoY
|
-1.32B
-2.70B – -741.01M
-60.4% YoY
|
-2.23B
-4.03B – -1.37B
-68.8% YoY
|
-2.68B
-4.84B – -1.64B
-20.2% YoY
|
-4.74B
-8.56B – -2.91B
-76.9% YoY
|
| Net Income |
-1.48B
est: -1.45B (-2.4%)
|
-677.61M
est: -927.40M (+26.9%)
|
-782.42M
est: -732.51M (-6.8%)
|
-882.92M
est: -897.52M (+1.6%)
|
-925.64M
est: -877.25M (-5.5%)
|
-405.43M
est: -166.43M (-143.6%)
|
-1.21B
est: -791.83M (-52.9%)
|
-657.33M
-1.35B – -326.77M
+17.0% YoY
|
-319.00M
-653.15M – -158.58M
+51.5% YoY
|
-163.29M
-334.33M – -81.17M
+48.8% YoY
|
-507.06M
-1.04B – -252.07M
-210.5% YoY
|
445.01M
221.22M – 911.13M
+187.8% YoY
|
| SGA |
161.64M
est: 32.53M (+397.0%)
|
130.34M
est: 32.81M (+297.3%)
|
191.26M
est: 178.81M (+7.0%)
|
328.02M
est: 1.68B (-80.4%)
|
376.46M
est: 2.34B (-83.9%)
|
383.12M
est: 2.55B (-85.0%)
|
523.44M
est: 1.20B (-56.4%)
|
2.17B
1.53B – 3.03B
+80.8% YoY
|
3.48B
1.95B – 7.13B
+60.4% YoY
|
5.88B
3.61B – 10.62B
+68.8% YoY
|
7.07B
4.33B – 12.76B
+20.2% YoY
|
12.50B
7.67B – 22.58B
+76.9% YoY
|
| EPS |
-12.69
est: -5.12 (-147.6%)
|
-3.14
est: -3.29 (+4.4%)
|
-3.07
est: -2.59 (-18.3%)
|
-3.35
est: -3.18 (-5.4%)
|
-3.28
est: -2.96 (-10.7%)
|
-1.37
est: -0.47 (-193.2%)
|
-3.43
est: -2.22 (-54.3%)
|
-1.85
-3.78 – -0.92
+17.0% YoY
|
-0.90
-1.83 – -0.45
+51.5% YoY
|
-0.46
-0.94 – -0.23
+48.8% YoY
|
-1.42
-2.92 – -0.71
-210.5% YoY
|
1.25
0.62 – 2.56
+187.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dajun Yang | Co-Founder, Chairman & Chief Executive Officer | 6M | — |
| Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | 237.5K | — |
| Hoi Yan Leung | Company Secretary | — | female |
| Jin Cao | Head of Finance | — | male |
| Manish Tandon | SVP of Business Development | — | — |
| Ming Guo | Co-Founder | — | — |
| Thomas Joseph Knapp | Senior Vice President & General Counsel | — | male |
| Veet Misra | Chief Financial Officer | — | — |
| Yifan Zhai | Chief Medical Officer | — | — |
| Yuly Chen | Senior Director of Investor Relations | — | — |
| Chongdong Fu | Senior Vice President & Head of CMC | — | — |
| Zhichao Si | Head of Commercial | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASPHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
